natgillin/translations-raw huggingface dataset:
HIV-1 infected patients receiving Truvada or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV infection, and therefore should remain under close clinical observation by physicians experienced in the treatment of patients with HIV associated diseases.
Pacijenti zaraženi virusom HIV-1 koji primaju Truvadu ili neku drugu antiretrovirusnu terapiju mogu i dalje razvijati oportunističke infekcije i druge komplikacije infekcije HIV-om pa stoga trebaju biti pod pažljivim kliničkim nadzorom liječnika s iskustvom u liječenju pacijenata s bolestima povezanima s HIV-om.
HIV-1 infected patients with mild to moderate renal impairment
Bolesnici zaraženi virusom HIV-1 s blagim do umjerenim oštećenjem funkcije bubrega
HIV-1 infected patients:
Pacijenti zaraženi virusom HIV-1:
HIV-1 infection:
Infekcija virusom HIV-1:
HIV-1 infection: The most frequently reported adverse reactions considered possibly or probably related to emtricitabine and/or tenofovir disoproxil fumarate were nausea (12%) and diarrhoea (7%) in an open-label randomised clinical study (GS-01-934, see section 5.1).
Infekcija virusom HIV-1: U otvorenom, randomiziranom kliničkom ispitivanju (GS-01-934), najčešće zabilježene nuspojave za koje se smatra da su moguće ili vjerojatno povezane s emtricitabinom i/ili tenofovirdizoproksilfumaratom, bile su mučnina (12%) i proljev (7%) (vidjeti dio 5.1).
HIV-1 integrase inhibitor (e.g. raltegravir);
HIV-1 inhibitori integraza (npr. raltegravir);
HIV-1 isolates (CRF01_AE, n=12; CRF02_AG, n=12; and Subtype C or CRF_AC, n=13) from 37 untreated patients in Africa and Asia were susceptible to abacavir (IC50 fold changes <2.5), and lamivudine (IC50 fold changes<3.0), except for two CRF02_AG isolates with fold-changes of 2.9 and for abacavir.
HIV-1 izolati (CRF01_AE, n=12; CRF02_AG, n=12; i podtip C ili CRF_AC, n=13) od 37 neliječenih bolesnika iz Afrike i Azije bili su osjetljivi na abakavir (IC50 promjena <2,5 puta), i lamivudin (IC50 promjena<3,0 puta), osim u slučaju dva CRF02_AG izolata u kojih je promjena za abakavir bila 2,9 i 3,4 puta.
HIV-1 isolates from 4 of these patients had developed resistance by Week 48 (total of 4 of 469 patients, 0.9%).
HIV-1 izolati 4 od tih bolesnika razvili su rezistenciju do 48. tjedna (ukupno 4 od 469 bolesnika, 0,9%).
HIV-1 isolates with reduced susceptibility (100-250-fold) to nevirapine emerge in cell culture.
Izolati HIV-a-1 sa smanjenom osjetljivošću (100–250 puta) na nevirapin uočeni su u staničnim kulturama.
HIV-1 isolates with reduced susceptibility to tenofovir alafenamide express a K65R mutation in HIV-1 RT; in addition, a K70E mutation in HIV-1 RT has been transiently observed.
Izolati virusa HIV-1 sa smanjenom osjetljivošću na tenofoviralafenamid izraţavaju mutaciju K65R u HIV-1 RT; dodatno je kratkotrajno uočena i mutacija K70E u HIV-1 RT.
HIV-1 RNA < 20 copies/mL
HIV-1 RNA < 20 kopija/ml
HIV-1 RNA < 50 copies/mL
HIV-1 RNK < 50 kopija/ml na prvotnom režimu liječenja
HIV-1 RNA < 50 copies/mla
HIV-1 RNK < 50 kopija/mla
HIV-1 RNA <50 copies/mL
HIV-1 RNA 50 kopija/ml
HIV-1 RNA <50 copies/ml
HIV-1 RNK < 50 kopija/ml
HIV-1 RNA <50 copies/mL
HIV-1 RNK <50 kopija/ml
HIV-1 RNA <50 copies/mL by baseline covariates
HIV-1 RNK < 50 kopija/ml prema početnim kovarijantama
HIV-1 RNA <50 copies/mL for those on ABC/3TC
HIV-1 RNK < 50 kopija/ml u bolesnika koji primaju ABC/3TC
HIV-1 RNA <50copies/mL for those on ABC/3TC
HIV-1 RNK <50 kopija/ml u bolesnika koji primaju ABC/3TC
HIV-1 RNA >100,000 copies/ml
HIV-1 RNK > 100 000 kopija/ml 8
HIV-1 RNA >100,000 copies/ml 8 %
HIV-1 RNK > 100 000 kopija/ml 8
HIV-1 RNA log10 mean change from baseline (log10 copies/ml)b
Prosječna promjena HIV-1 RNK log10 u odnosu na početnu vrijednost (log10 kopija/ml)b
HIV-1 RNA ≥ 50 copies/mLc
HIV-1 RNK ≥ 50 kopija/mlc
HIV-1 uninfected individuals should be counselled to strictly adhere to the recommended Truvada dosing schedule.
Osobama koje nisu zaražene virusom HIV-1 treba savjetovati da se strogo pridržavaju preporučenog rasporeda doziranja Truvade.
HIV-1: Approximately one third of patients can be expected to experience adverse reactions following treatment with tenofovir disoproxil fumarate in combination with other antiretroviral agents.
HIV-1: Može se očekivati da će približno jedna trećina pacijenata razviti nuspojave nakon liječenja tenofovirdizoproksilfumaratom u kombinaciji s drugim antiretrovirusnim lijekovima.
HIV-1: In adolescents aged 12 to < 18 years and weighing ≥ 35 kg, the recommended dose of Viread is 245 mg (one tablet) once daily taken orally with food (see sections 4.8 and 5.1).
HIV-1: U adolescenata u dobi od 12 do < 18 godina i tjelesne težine ≥ 35 kg, preporučena doza Vireada je 245 mg (jedna tableta) jedanput na dan koja se uzima peroralno s hranom (vidjeti dijelove 4.8 i 5.1).
HIV-1: In study GS-US-104-0321, 87 HIV-1 infected treatment-experienced patients 12 to < 18 years of age were treated with tenofovir disoproxil fumarate (n = 45) or placebo (n = 42) in combination with an optimised background regimen (OBR) for 48 weeks.
HIV-1: U ispitivanju GS-US-104-0321, 87 prethodno liječenih pacijenata zaraženih virusom HIV-1, u dobi od 12 do 18 godina starosti, primali su tenofovirdizoproksilfumarat (n = 45) ili placebo (n = 42) u kombinaciji s optimiziranim pozadinskim režimom (OBR) tijekom 48 tjedana.
HIV-1: Steady-state pharmacokinetics of tenofovir were evaluated in 8 HIV-1 infected adolescent patients (aged 12 to < 18 years) with body weight ≥ 35 kg.
HIV-1: Farmakokinetika tenofovira u stanju dinamičke ravnoteže procijenjena je u 8 adolescentnih pacijenata zaraženih HIVom (u dobi od 12 do 18) s tjelesnom težinom ≥ 35 kg.
HIV-1: The recommended dose is 6.5 mg of tenofovir disoproxil (as fumarate) per kilogram of body weight once daily taken with food.
HIV-1: Preporučena doza je 6,5 mg tenofovirdizoproksila (u obliku tenofovirdizoproksilfumarata) po kilogramu tjelesne težine koja se se uzima jedanput na dan s hranom.
HIV-1infected patients with pre-existing liver dysfunction, including chronic active hepatitis, have an increased frequency of liver function abnormalities during combination antiretroviral therapy (CART) and should be monitored according to standard practice.
Pacijenti zaraženi virusom HIV-1 i s otprije postojećim poremećajem funkcije jetre, uključujući kronični aktivni hepatitis, imaju povećanu učestalost abnormalnosti funkcije jetre tijekom kombinirane antiretrovirusne terapije (engl. combination antiretroviral therapy, CART), pa ih treba pratiti u skladu sa standardnom praksom.
HIV-ANTIVIRAL AGENTS: HIV-PROTEASE INHIBITORS (PIs)
ANTIVIRUSNI LIJEKOVI PROTIV HIV-a: INHIBITORI HIV PROTEAZE (IP)
HIV-ANTIVIRAL AGENTS: REVERSE TRANSCRIPTASE INHIBITORS
ANTIVIRUSNI LIJEKOVI PROTIV HIV-a: INHIBITORI REVERZNE TRANSKRIPTAZE
HIV-HCV co-infected patients
Bolesnici s HIV-HCV koinfekcijom
HIV-HCV coinfection
Bolesnici s HIV-HCV koinfekcijom
HIV-HCV patients receiving Pegasys and ribavirin combination therapy other undesirable effects have been reported in ≥ 1% to ≤ 2% of patients: hyperlactacidaemia/lactic acidosis, influenza, pneumonia, affect lability, apathy, tinnitus, pharyngolaryngeal pain, cheilitis, acquired lipodystrophy and chromaturia.
Za ≥ 1% do ≤ 2% bolesnika zaraženih HIV-om i HCV-om na kombiniranom liječenju lijekom Pegasys i ribavirinom, prijavljene su i druge nuspojave: hiperlaktacidemija/laktična acidoza, gripa, upala pluća, afektivna labilnost, apatija, tinitus, bol u ždrijelu i grkljanu, heilitis, stečena lipodistrofija i kromaturija.
HIV-infected adults with conserved immune function
Odrasli zaraženi HIV-om s očuvanom funkcijom imunološkog sustava
HIV-infected adults with conserved immune function
Odrasli zaraženi HIV-om s očuvanom imunološkom funkcijom
HIV-infected patients
Bolesnici zaraženi HIV-om
HIV-infected patients with signs of moderate liver disease;
bolesnika s HIV-om koji iskazuju znakove umjerenih problema s jetrom;
HIV-infected subjects
Osobe zaražene virusom HIV-a
HIV-Negative Matched Control Subjects
HIV-negativni podudarni kontrolni ispitanici
HIV-Positive Subjects
HIV-pozitivni ispitanici
HIV-positive, paediatric patients, aged 2 through 18 years, were studied in a randomized, open-label, multicenter study (trial 1182.14).
HIV-pozitivni pedijatrijski bolesnici, u dobi 2 do 18 godina, bili su uključeni su u randomizirano, otvoreno, multicentrično kliničko ispitivanje (ispitivanje 1182.14).
HIV-RNA
(N=237)
HIV/AIDS, leukaemia, lymphoma, common variable immunodeficiency, or those who require high-dose steroids or other immunosuppressive agents)
HIV/AIDS, leukemija, limfom, obična varijabilna imunodeficijencija ili oni u kojih su potrebne visoke doze steroida ili drugih imunosupresiva)
HIV/HBV co-infected patients not receiving concomitant HAART: entecavir has not been evaluated in HIV/HBV co-infected patients not concurrently receiving effective HIV treatment.
Bolesnici istodobno inficirani HIV-om i HBV-om koji nisu istodobno primali HAART: entekavir se nije ispitivao u bolesnika istodobno inficiranih i HIV-om i HBV-om koji nisu istodobno primali učinkovito liječenje protiv HIV-a.
HIV/HBV co-infected patients receiving concomitant HAART: study 038 included 67 HBeAg positive and 1 HBeAg negative patients co-infected with HIV.
Bolesnici istodobno inficirani HIV-om i HBV-om koji su istodobno primali HAART: ispitivanje 038 uključilo je 67 HBeAg pozitivnih i 1 HBeAg negativnog bolesnika istodobno inficiranih HIV-om.
HIV/HBV or HCV co-infected patients
Bolesnici istodobno zaraženi HIV-om i HBV-om ili HCV-om
HIV/HBV or HCV co-infected patients
Pacijenti istovremeno zaraženi HIV-om i HBV-om ili HCV-om
HIV/HBV or HCV co-infected patients: Only a limited number of patients were co-infected with HBV (n = 13) or HCV (n = 26) in study GS-01-934.
Pacijenti istovremeno inficirani HIV/HBV-om ili HCV-om: U ispitivanju GS-01-934 samo je ograničeni broj pacijenata bio istovremeno zaražen HBV-om (n=13) ili HCV-om (n=26).
HIV/HBV or HCV co-infected patients: The adverse reaction profile of emtricitabine and tenofovir disoproxil fumarate in a limited number of HIV-infected patients in study GS-01-934 who were co- infected with HBV (n=13) or HCV (n=26) was similar to that observed in patients infected with HIV without co-infection.
Pacijenti istovremeno zaraženi HIV/HBV-om ili HCV-om: U ispitivanju GS-01-934, profil nuspojava emtricitabina i tenofovirdizoproksilfumarata u ograničenog broja pacijenata zaraženih HIV-om koji su istovremeno bili zaraženi HBV-om (n = 13) ili HCV-om (n = 26) bio je sličan profilu koji je zapažen u pacijenata zaraženih virusom HIV-a bez istovremene druge infekcije.
hivering
drhtanje
hivering
drhtavica
hivering, feeling generally unwell
drhtavica, opće loše osjećanje
hivering, feeling generally unwell
drhtavica, opće loše osjećanje,
hivering, lack of energy, swelling, pain
drhtanje, nedostatak energije, oticanje, bolovi
hivers
drhtanje
hives
koprivnjača
hives
koprivnjače
hives
koprivnjaču
Hives (itchy, bumpy rash)
koprivnjača (izdignut osip koji svrbi)
hives (nettle rash)
koprivnjača (pelenski osip)
hives (or "nettle rash"), itching, hair loss, eczema, dry skin, skin redness, acne
koprivnjača, svrbež, gubitak kose, ekcem, suha koža, crvenilo kože, akne
hives (or "nettle rash"), itching, hair loss, eczema, dry skin, skin redness, acne an increase of CPK (creatine phosphokinase) in your blood, an enzyme which is sometimes released with muscle breakdown, muscle spasms, joint stiffness, muscle weakness, neck pain
koprivnjača, svrbež, gubitak kose, ekcem, suha koža, crvenilo kože, akne povišenje CPK (kreatin fosfokinaza) u krvi, enzim koji se ponekad otpušta tijekom razgradnje mišića, mišićni grčevi, ukočenost zglobova, mišićna slabost, bol u vratu
hives (or “nettle rash”), hair loss, eczema, acne an increase of CPK (creatine phosphokinase) in your blood, an enzyme which is sometimes released with muscle breakdown, muscle spasms, joint stiffness, joint swelling, muscle weakness, neck pain
koprivnjača, gubitak kose, ekcem, akne povišenje CPK (keratin fosfokinaza) u krvi, enzim koji se ponekad oslobađa pri pucanju mišića, mišićni grčevi, ukočenost zglobova, oticanje zglobova, mišićna slabost, bol u vratu
Hives (red bumps on your skin, that are sometimes itchy).
koprivnjača (crvene izbočine na koži, ponekad praćene svrbežom)
hives (urticaria)
koprivnjača (urtikarija)
Hives (urticaria)
Koprivnjača (utrikarija)
hives (urticaria) dehydration.
koprivnjača (urtikarija); dehidracija.
Hives (urticaria), redness and irritation (dermatitis) and itching (pruritus) at the vaccination-site; flushing
koprivnjača (urtikarija), crvenilo i nadraženost (dermatitis) te svrbež (pruritus) na mjestu cijepljenja; crvenilo praćeno osjećajem žarenja
Hives (urticaria).
koprivnjača (urtikarija)
Hives and difficulties to breathe.
Koprivnjača i poteškoće u disanju
hives rash
koprivnjaču osip
Hives, generalised itching
koprivnjača, opći svrbež
hives, increased sweating, night sweats
koprivnjača, pojačano znojenje, noćno znojenje
hives, inflammation of the skin, redness of the skin, dry skin, red or purple spots under the skin, skin color disorder, increased sweating
koprivnjača, upala kože, crvenilo kože, suha koža, crvene ili ljubičaste mrlje pod kožom, poremećaj boje kože, pojačano znojenje
Hives, itching
koprivnjača, svrbež
Hives, itching, increased sweating, dehydration
koprivnjača, svrbež, pojačano znojenje, dehidracija
hives, rash, itching
koprivnjača, osip, svrbež
Hives, rash, itching
Urtikarija, osip, svrbež
Hives, rash, itching, difficulty breathing or swallowing (frequency not known, cannot be estimated from the available data); these are signs of an allergic reaction.
Koprivnjača, osip, svrbež, otežano disanje ili gutanje (učestalost nije poznata, ne može se procijeniti iz dostupnih podataka); ovo su znakovi alergijske reakcije.
Hives, red itchy bumps on your skin (urticaria)
Koprivnjača, crvena uzdignuća kože koja svrbe (urtikarija)
hives.
koprivnjača
hives/ localised swelling of the skin or lining of the mouth or throat
koprivnjača/lokalizirano oticanje kože ili sluznice usta ili grla
Hives/nettle rash and itching
koprivnjača i svrbež
Hives;
Koprivanjača;
Hives;
Koprivnjača;
hives; swelling in your hands, feet, ankles, face, lips, mouth or throat which may cause difficulty in swallowing or breathing.
urtikariju; oticanje ruku, stopala, gležnjeva, lica, usana, usta ili grla što može izazvati otežano gutanje ili disanje.
HIV1 patient isolates with reduced susceptibility to indinavir expressed varying patterns and degrees of cross–resistance to a series of diverse HIV PIs, including ritonavir and saquinavir.
Na izolatima bolesnika zaraženih s HIV1 sa smanjenom osjetljivošću na indinavir utvrđeni su različiti uzorci i stupnjevi križne rezistencije na niz različitih inhibitora HIV proteaze, uključujući ritonavir i sakvinavir.
Hizentra 200 mg/ml solution for subcutaneous injection
Hizentra 200 mg/ml otopina za potkožnu injekciju
Hizentra 200 mg/ml solution for subcutaneous injection human normal immunoglobulin (SCIg)
Hizentra 200 mg/ml otopina za potkožnu injekciju ljudski normalni imunoglobulin (s.c.Ig)
Hizentra comes as a ready-to-use solution in single-use vials.
Hizentra je dostupna kao otopina spremna za primjenu u jednokratnim bočicama.
Hizentra contains approximately 250 mmol/L (range: 210 to 290) of L-proline.
Hizentra sadrži približno 250 mmol/L (raspon od: 210 do 290) L-prolina.
Hizentra contains residual amounts of IgA which might cause an allergic reaction.
Hizentra sadržava ostatne količine IgA koje bi mogle prouzročiti alergijsku reakciju.
Hizentra has no or negligible influence on the ability to drive and use machines.
Hizentra ima zanemariv ili nikakav utjecaj na sposobnost upravljanja vozilima i strojevima.
Hizentra human normal immunoglobulin (SCIg)
Hizentra ljudski normalni imunoglobulin (s.c.Ig)
Hizentra is a ready-to-use solution (see section 5 “How to store Hizentra” and section 6 “What Hizentra looks like and contents of the pack”).
Hizentra je gotova otopina (vidjeti dio 5 "Kako čuvati Hizentru" i poglavlje 6 "Sadržaj pakovanja i dodatne informacije").
Hizentra is a solution for injection under the skin.
Hizentra je otopina za potkožnu injekciju.
Hizentra is a solution for subcutaneous injection (200 mg/ml).
Hizentra je otopina za supkutanu injekciju (200 mg/ml).
Hizentra is essentially sodium free.
Hizentra je u osnovi lijek bez natrija.
Hizentra is given as a subcutaneous infusion (very
Hizentra se daje putem potkožne infuzije
Hizentra is used in patients whose blood does not contain enough antibodies (proteins that help the body to fight infections and other diseases), also known as immunoglobulins.
Hizentra se primjenjuje u bolesnika čija krv ne sadrži dovoljno protutijela (proteina koji tijelu pomažu u borbi protiv infekcija i drugih bolesti) koja su također poznata pod nazivom imunoglobulini.
Hizentra may be injected into sites such as abdomen, thigh, upper arm, and lateral hip.
Hizentra može biti injicirana na mjesta kao što su trbuh, bedra, nadlaktice i lateralna strana kuka.
Hizentra may impair the effect of some live virus vaccines such as measles, rubella, mumps and chicken pox.
Ovaj lijek može umanjiti učinak nekih živih virusnih cjepiva, kao što su ona za ospice, rubeolu, zaušnjake i vodene kozice.
Hizentra must not be used in patients with hyperprolinaemia (a genetic disorder causing high levels of the amino acid proline in the blood).
Hizentra se ne smije primjenjivati u bolesnika s hiperprolinemijom (genetski poremećaj koji uzrokuje visoke razine aminokiseline prolina u krvi).
Hizentra was evaluated in 33 paediatric subjects (21 children [3 to 11 years] and 12 adolescents [12 to 16 years]) with primary immunodeficiency disease (PID).
Hizentra je evaluirana u 33 pedijatrijska ispitanika (21 djece [3 do 11 godina] i 12 adolescenata [12 do 16 godina]) s bolešću primarne imunodeficijencije (PID).
Hizentra works by restoring abnormally low IgG levels to their normal range in the patient’s blood.
Hizentra djeluje tako da omogućuje da abnormalno niske razine IgG-a u krvi bolesnika opet postanu normalne.
HLA-B* 1502 allele - in Han Chinese, Thai and other Asian populations
Prisutnost alela HLA-B*1502 u populacijama pripadnika kineskog naroda Han, pripadnika naroda Tai i pripadnika drugih azijskih naroda.
HLA-B* 1502 in individuals of Han Chinese and Thai origin has been shown to be strongly associated with the risk of developing the severe cutaneous reactions known as Stevens Johnson syndrome (SJS) when treated with carbamazepine.
Alel HLA-B*1502 u pojedinaca porijeklom iz kineskog naroda Han i naroda Tai snažno je povezan s rizikom od razvoja teške kožne reakcije poznate kao Stevens-Johnsonov sindrom (SJS), kada se oni liječe karbamazepinom.
HLA-B*5701 screening for risk of ABC hypersensitivity should never be substituted for appropriate clinical vigilance and patient management in individuals receiving ABC.
Probir na HLA- B*5701 radi utvrđivanja rizika od preosjetljivosti na abakavir nikad ne smije biti zamjena za odgovarajuće kliničko praćenje i zbrinjavanje pojedinaca koji primaju abakavir.
HLA-B*5701 status must always be documented and explained to the patient prior to initiating therapy.
HLA- B*5701status mora uvijek biti dokumentiran i objašnjen bolesniku prije početka liječenja.
HLA-B*5701 status must always be documented and explained to the patient prior to initiating therapy.
HLA-B* 5701 status mora uvijek biti dokumentiran i objašnjen bolesniku prije početka liječenja.
HLA-B*5701 status must always be documented and explained to the patient prior to initiating therapy.
HLA-B*5701 status mora uvijek biti dokumentiran i objašnjen bolesniku prije početka liječenja.
HLA-B*5701 status must always be documented prior to initiating therapy.
Status HLA-B*5701 mora se uvijek dokumentirati prije početka liječenja.
HMG Co-A Reductase Inhibitor
Inhibitori HMG Co-A reduktaze
HMG CO-A REDUCTASE INHIBITORS
INHIBITORI HMG KO-A REDUKTAZE
HMG Co-A Reductase Inhibitors
Inhibitori reduktaze HMG Co- A
HMG CO-A REDUCTASE INHIBITORS
INHIBITORI REDUKTAZE HMG-CoA
HMG Co-A Reductase Inhibitors
periodički kontrolirati.
HMG CoA REDUCTASE INHIBITOR
INHIBITORI HMG-CoA REDUKTAZE
HMG CoA reductase inhibitors
Inhibitori HMG CoA reduktaze
HMG CoA REDUCTASE INHIBITORS
INHIBITORI HMG-KoA REDUKTAZE
HMG-CoA reductase
HMG-CoA reduktaze mogu
HMG-CoA reductase inhibitors
Inhibitori HMG-KoA reduktaze
HMG-CoA REDUCTASE INHIBITORS
INHIBITORI REDUKTAZE HMG-CoA
HMG-CoA reductase inhibitors
sakvinavira/ritonavira.
HMG-CoA reductase inhibitors may cause myopathy, including rhabdomyolysis, the combination of these agents with lopinavir/ritonavir is contraindicated (see section 4.3).
Primjena avanafila s lopinavirom/ritonavirom je kontraindicirana (vidjeti dio 4.3).
HMG-CoA REDUCTASE INHIBITORS Same recommendations as for indinavir without ritonavir boosting (see Table 1).
INHIBITORI HMG-CoA REDUKTAZE Vrijede iste preporuke kao i za indinavir koji nije pojačan ritonavirom (vidjeti Tablicu 1).
HMG-CoA reductase inhibitors which are highly dependent on CYP3A metabolism, such as lovastatin and simvastatin, are expected to have markedly increased plasma concentrations when co-administered with ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer.
Očekuje se da će se koncentracije inhibitora HMG-CoA reduktaze u plazmi, koji su izrazito ovisni o metabolizmu posredovanom enzimima CYP3A , poput lovastatina i simvastatina, znatno povećati pri njihovoj istodobnoj primjeni s ritonavirom doziranim kao antiretrovirusnim lijekom ili kao farmakokinetičkim pojačivačem.
hoarse voice
hrapav glas
hoarseness
promuklost
Hoarseness (dysphonia)
Promuklost (disfonija)
hock
šok
hock*, serum
erumska bolest,
hock,
šok,
hock, intravascular administration of iodinated contrast agents (see section 4.4).
šok, intravaskularna primjena jodnih kontrasta (vidjeti dio 4.4).
hock;
šok;
Hoddesdon Hertfordshire EN11 9BU United Kingdom
Hoddesdon Hertfordshire EN11 9BU Ujedinjeno Kraljevstvo
Hoddesdon Hertfordshire EN11 9BU United Kingdom
Hoddesdon Hertfordshire EN11 9BU Velika Britanija
Hoddesdon, Hertfordshire, EN11 9BU United Kingdom
Hoddesdon, Hertfordshire, EN11 9BU Ujedinjeno Kraljevstvo
Hodgkin lymphoma;
Hodgkinov limfom;
Hold a 75 mg capsule upright over a bowl and carefully snip off the rounded tip with scissors.
Držite kapsulu od 75 mg uspravno iznad jedne zdjelice te škarama pažljivo odrežite zaobljeni vrh.
Hold a swab on the injection site.
Stavite gazu na mjesto injiciranja.
Hold Avonex Pen so that the cap is pointing up.
Držite Avonex Pen tako da je zatvarač okrenut prema
Hold bosutinib until ANC  1.0×109/L and platelets  50×109/L.
Obustaviti bosutinib sve do ABN-a  1,0×109/l i trombocita  50×109/l.
Hold bottle and syringe securely tight.
Čvrsto držite bočicu i štrcaljku.
Hold Dose Knob in and count to 5 slowly.
Držite gumb za doziranje pritisnutim i polako izbrojite do 5.
Hold down dosing button until beeping stops and display goes blank
Držite pritisnuto dugme za doziranje dok se zvučni signal ne prestane oglašavati i dok prikaz ne nestane sa zaslona
Hold down dosing button until beeping stops and display goes blank.
Držite pritisnuto dugme za doziranje dok se zvučni signal ne prestane oglašavati i dok prikaz ne nestane sa zaslona.
Hold down dosing button until display goes blank
Držite pritisnuto dugme za doziranje dok prikaz ne nestane sa zaslona
Hold down dosing button until display goes blank.
Držite pritisnuto dugme za doziranje dok prikaz ne nestane sa zaslona.
Hold down TachoSil with a gentle pressure for 3-5 minutes.
Pridržite ga laganim pritiskom 3-5 minuta.
Hold for 10 seconds to make sure you get the full dose.
10 sekundi kako biste bili sigurni da ste primili cijelu dozu.
Hold gauze on the injection site for approximately 30 seconds.
Držite gazu na mjestu uboda približno 30 sekundi.
Hold InnoLet with the needle upwards and tap the cartridge gently with your finger a few times (picture B) to make any air bubbles collect at the top of the cartridge.
InnoLet držite iglom okrenutom prema gore te nekoliko puta lagano kucnite prstom po ulošku (slika B) kako bi se mjehurići zraka skupili na vrhu uloška.
Hold it in and count to 5 s-l-o- w-l-y.
Držite ga pritisnutim i brojite p-o-l-a-k-o do 5.